Lilly CEO says weight-loss drug shortage to end ‘very soon’, Health News, ET HealthWorld

London: U.S. drugmaker Eli Lilly expects its blockbuster weight-loss drug to officially come out of shortage in the United States in coming days, Bloomberg News reported on Thursday, citing an interview with the company’s CEO, David Ricks.

Lilly’s drug, tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight management, will cease to be in shortage “very soon,” CEO David Ricks said in an interview with Bloomberg in Paris.

The U.S. Food and Drug Administration’s website lists some doses of Mounjaro and Zepbound as being in limited supply. Mounjaor has been on the FDA’s shortage list since late 2022.

Lilly and the FDA did not immediately respond to Reuters’ requests for comment.

Lilly said in April that it expects supply of Zepbound to remain “quite tight” in the near and midterm as it ramps up capacity.

Eli Lilly and Danish rival Novo Nordisk are racing to increase production in a weight-loss drug market estimated to reach about $150 billion by early 2030s. Both the companies’ obesity treatments belong to a class of drugs originally developed for diabetes known as GLP-1 agonists.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Maju Samuel)